

Special Issue

Breast Cancer: Novel Insights into Hormone Therapy

Message from the Guest Editor

Endocrine therapy is the standard of care in hormone-receptor-positive breast cancer (HR+ BC). CDK4/6 inhibitors are now part of clinical practice in adjuvant and metastatic settings. Other new drugs (SERDs, CDK7 inhibitors, and PI3K/akt/mTor inhibitors) are increasingly appearing in metastatic settings. Moreover, antibody-drug conjugates (ADCs) have recently demonstrated their clinical efficacy regardless of the expression of hormone receptors, as have PROTACTs (PROteolysis Targeting Chimeras), new small molecules designed to escape endocrine resistance mechanisms. The aim of this Special Issue is to report the state of the art in the treatment of HR+ BC and analyze the new challenges to be addressed: redefining escalation and de-escalation strategies based on the risk of disease recurrence in an adjuvant setting and on the disease burden in a metastatic setting; identifying the optimal treatment sequence; understanding the role of ADCs in HR+ BC and the role of predictive biomarkers of responses that have been identified so far (PI3K, BRCA, and ESR1 mutations, as well as, more recently, the low expression of HER2).

Guest Editor

Dr. Palma Fedele

Oncology Unit, Dariuio Camberlingo Hospital, Francavilla Fontana, ASL Brindisi, Brindisi, Italy

Deadline for manuscript submissions

closed (20 April 2024)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/158164

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).